FDA Accepts sBLA of Dupilumab for Asthma
Biologic drug demonstrates efficacy in moderate-to-severe asthma.
Sanofi recently announced that the FDA has accepted the supplemental Biologics License Application (sBLA) of dupilumab (Dupixent) for the maintenance treatment of asthma, according to a press release.
Sanofi is seeking approval for dupilumab as an add-on therapy for adults and adolescents with moderate-to-severe asthma.
The PDUFA date for this indication is October 20, 2018, according to the release.
Related Coverage:
Dupilumab is a human monoclonal antibody designed to inhibit interleukin-4 and interleukin-13 cytokines, which are known to contribute to asthma-related inflammation. These patients typically experience type 2 allergic inflammation, which is characterized by an imbalance of immune cells and other proteins.
Patients with moderate-to-severe asthma typically experience exacerbations that may result in emergency department visits and hospitalizations, according to Sanofi. There is currently an unmet need for patients with asthma who experience decreased lung function, severe attacks, long-term corticosteroid use, and poor quality of life, according to the release.
The new sBLA was the result of positive findings from 3 clinical trials from the LIBERTY ASTHMA drug development program, which included 2888 adults and adolescents with moderate-to-severe asthma.
Sanofi plans to submit findings from the phase 3 QUEST and VENTURE clinical trials to medical meetings in 2018, according to the release.
Dupilumab is currently under clinical development for asthma, meaning that the safety and efficacy in this patient population has not been evaluated by regulatory authorities.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025